Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Therapeutic promise of CRISPR-Cas9 gene editing in sickle cell disease and β-thalassemia: A current review

12 Apr 2025

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CRISPR and Genetic Engineering
Share to Innovation and Socioeconomic Development
Share to SARS-CoV-2 and COVID-19 Research

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 40252393
DOI: 10.1016/j.retram.2025.103513

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Therapeutic promise of CRISPR-Cas9 gene editing in sickle cell disease and β-thalassemia: A current reviewPMID 40252393Read ↗

CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-ThalassemiaSemantic proximity Read ↗

CRISPR/Cas9 gene editing for curing sickle cell diseaseSemantic proximity Read ↗

CRISPR/Cas9-based gene-editing technology for sickle cell diseaseSemantic proximity Read ↗

Therapeutic Applications of CRISPR-Cas9 Gene EditingSemantic proximity Read ↗

Recent advancements in gene therapy for sickle cell disease and β-thalassemiaSemantic proximity Read ↗

Current landscape of gene‐editing technology in biomedicine: Applications, advantages, challenges, and perspectivesSemantic proximity Read ↗

CRISPR/Cas9, a promising approach for the treatment of β-thalassemia: a systematic review.Semantic proximity Read ↗

Therapeutic gene editing strategies using CRISPR-Cas9 for the β-hemoglobinopathiesSemantic proximity Read ↗

Gene editing for sickle cell disease and transfusion dependent thalassemias- A cure within reachSemantic proximity Read ↗

β-Thalassemia gene editing therapy: Advancements and difficultiesSemantic proximity Read ↗

CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-ThalassemiaSemantic proximity Read ↗

Advances in genome editing: the technology of choice for precise and efficient β-thalassemia treatmentSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.